Human pluripotent stem cells are a biological resource most commonly considered for their potential in cell therapy or, as it is now called, 'regenerative medicine'. However, in the near future, their most important application for human health may well be totally different, as they are more and more envisioned as opening new routes for pharmacological research. Pluripotent stem cells indeed possess the main attributes that make them theoretically fully equipped for the development of cell-based assays in the fields of drug discovery and predictive toxicology. These cells are characterized by: (i) an unlimited self-renewal capacity, which make them an inexhaustible source of cells; (ii) the potential to differentiate into any cell phenotype of the body at any stage of differentiation, with probably the notable exception, however, of the most mature forms of many lineages; and (iii) the ability to express genotypes of interest via the selection of donors, whether they be of embryonic origin, through pre-implantation genetic diagnosis, or adults, by genetic reprogramming of somatic cells, so-called iPSCs (induced pluripotent stem cells). In the present review, we provide diverse illustrations of the use of pluripotent stem cells in drug discovery and predictive toxicology, using either human embryonic stem cell lines or iPSC lines.
Introduction
Attrition, the progressive reduction of medicinal products along the lengthy path between 'hit' identification and the market, has become the most concerning issue in the pharmaceutical industry over the last decade. Although the development cost of a marketable product, estimated at US$500 million at the end of the 20th Century, was reevaluated to be US$900 million in 2004 [1] , and has clearly still been progressing rapidly since, the number of new molecules finally authorized into the market is decreasing steadily. A total of 36 new medicines were approved by the FDA (Food and Drug Administration) in 2004, only 20 in 2005 [2] , and the slightly more optimistic trend at the beginning of the second decade of the 21st Century is only based on the emergence of biological products, vaccines and therapeutic proteins. Attrition is essentially due to the inappropriateness of the products in development in terms of efficacy or safety, but a major issue here is the delay in the identification of the problems, which is extremely costly. In 2001, for example, 30% of medicines that entered clinical trials were weeded out due to a lack of efficiency and 30% of others because of safety concerns [1] . Reducing attrition at the clinical development stage has therefore become one of the main objectives of research and development in the pharmacological industry and most attention is devoted, in particular, to the development of more predictive in vitro models for the early testing of drug candidates that would allow a significant reduction in investment [3] . The pharmaceutical industry is not the only one to be concerned. The environmental concerns [exemplified in Europe by the REACH (Registration, Evaluation, Authorization and Restriction of Chemical substances) directive on the evaluation of chemicals], as well as the pressure against animal testing in the cosmetics industry, confirm the urgent need to develop new robust and economic in vitro models [4] . We are advocating in the present review that, owing to their unique properties, hESCs {human ESCs [embryonic SC (stem cells)]}, but also the more recently described iPSCs (induced pluripotent SCs), might contribute to it.
A need for new more predictive models of human physiology and pathology
During all of the steps of drug development, models play a decisive role. The first to be used are models of pathology that enable pathogenesis mechanisms to be investigated and a relevant target(s) to be identified to screen chemical compound libraries in the search for drug candidates. These so-called 'hits' are then evaluated again in models for their pharmacokinetic and safety properties. With a view to (i) limiting animal testing, as motivated by ethical reasons and cost, but also for relevance as physiological interspecies differences can be most confusing, Thomson et al. [7] reported the establishment of the first hESC line. These cells are derived from the inner cell mass of blastocysts obtained after in vitro fertilization. They display an unlimited self-renewal capacity and are pluripotent, i.e. are able to give rise to all of the different cell types that constitute an organism (Figure 1 ). More recently, Shinya Yamanaka and his co-workers [8,9] have identified a technique based upon genetic engineering that permits the reprogramming of adult cells into pluripotent SCs with ESC-like characteristics [8, 9] , the now famous iPSCs. These iPSCs were obtained by reprogramming somatic cells with a combination of four transcription factors [Oct3/4 (octamer-binding protein 3/4), SOX2, KLF4 (Krüppel-like factor 4) and c-MYC] (Figure 1) .
In the present review, we aim to illustrate how their unique properties (Table 1) confer on pluripotent-SC-based models the potential to revolutionize the earliest steps of drug discovery and, in particular, the stages of pathological and toxicology modelling, by providing physiological models for any human cell type at the desired amount.
Pluripotent SCs and pathological modelling
hESC disease models hESCs may be used to model human diseases in two different ways: (i) by inducing a mutation in hESCs derived from healthy embryos, as reported by Urbach et al. [10] in the creation of a model for Lesch-Nyhan disease using homologous recombination generating a mutation in the HPRT1 (hyperparathyroidism 1) gene in wild-type hESCs; or (ii) by using hESCs derived from embryos identified during PGD (pre-implantation genetic diagnosis) that express naturally causal mutations [11] [12] [13] [14] . The establishment of such PGD-hESC lines has already been reported for more than 20 diseases, including thalassaemia, adrenoleukodystrophy, Duchenne and Becker muscular dystrophies, Steinert disease and fragile X syndrome [15] . PGD-hESCs represent a more relevant model than genetically engineered hESCs to study pathological mechanisms involved in a genetic disease, as they exhibit the same genotype and related defects [16] . hESCs can constitute an ideal model to study developmentally regulated events involved in disease progression, as in fragile X syndrome, where early events in FMR1 (fragile X mental retardation 1) gene silencing might not be characterized due to the lack of an appropriate model. In order to study mechanisms by which the normal expression of FMR1 is inactivated during early embryonic development, Eiges et al. [17] used PGD-hESCs to demonstrate epigenetic changes that occur upon differentiation at the origin of this gene silencing.
iPSCs may be obtained from any donor of interest
Besides the common characteristics and properties that they share with hESCs, iPSCs present the additional advantage that they could be derived from any patient whose disease is to be studied. Therefore iPSCs allow the access to: (i) diseases There are two types of human pluripotent SCs: hESCs and iPSCs. Both are characterized by two distinctive properties, their unlimited self-renewal capacity in an undifferentiated state and their competence to differentiate into all derivatives of the three germ layers (endoderm, mesoderm and ectoderm). hESCs are obtained from embryos without parental project, left over after in vitro fertilization. They are derived after isolation of the inner cell mass at the blastocyst stage (day 5/6 of development). hESCs from embryos expressing naturally causal mutations, identified by PGD, can be used as disease models.
iPSCs are generated by reprogramming of adult somatic cells (e.g. skin fibroblasts) with transcription factors. For pathological modelling, they can be obtained from patients.
whose mutation is known but not identified by PGD; and (ii) pathologies whose causal mutation is unknown. Moreover, they enable the expression of the pathology in the cellular model to be correlated with the patient's symptoms.
It is possible to produce patient-specific iPSCs from young [18] as well as old [19] patients. Dimos et al. [19] reported in 2008 the generation of iPSCs from an 82-year-old woman diagnosed with a familial form of amyotrophic lateral sclerosis. These patient-specific iPSCs were successfully differentiated into motoneurons. iPSCs are able to functionally reproduce a genetic disease, as exemplified by the demonstration that motoneurons differentiated from an iPSC model of spinal muscular atrophy reproduced selective pathological defects [18] . They display a marked reduction in size and number, a decreased expression of the SMN1 (survival of motor neuron 1) gene as well as delayed synapse formation. A more complete demonstration of the interest in iPSCs in obtaining new insights concerning pathogenesis and treatment was published recently by Lee et al. [20] concerning familial dysautonomia. Using patientspecific iPSCs that expressed disease-specific biomarkers, they tested candidate molecules for their ability to reverse the aberrant splicing of the IKBKAP (inhibitor of κ light polypeptide gene enhancer in B-cells, kinase complexassociated protein) gene in order to improve neuronal differentiation and migration. They validated kinetin as an interesting candidate compound for this pathology.
These different studies emphasize the usefulness of pluripotent SCs as a tool to study disease mechanisms, either at the undifferentiated stage or in specific cell types. They can theoretically provide relevant models for any pathology, including neurological disorders and rare diseases that are difficult to analyse in vitro at this point. Moreover, as they are compatible with a miniaturized format, they open the way to screening techniques using genomic resources and chemical libraries.
Pluripotent SCs and predictive toxicology
Pluripotent SCs may also enable the evaluation of identified candidates for different parameters in preclinical studies, in particular for their safety which represents a crucial issue.
The EST (ESC test): a logical application for an embryonic model
ESCs already constitute an excellent model in reprotoxicology for what they are, i.e. one of the earliest models of ontogenesis (Figure 2 ). Hence the EST was set up by ECVAM (European Center for the Validation of Alternative Methods) more than a decade ago. This test evaluates a drug's cytotoxicity and its inhibitory effect on the spontaneous differentiation of murine ESCs into functional contractile cardiomyocytes in embryoid bodies [21] . In a test of 20 compounds, well-characterized in vivo in terms of reprotoxicity, the EST correctly classified 78% of them as non-, weak or strong embryotoxic [22] . Given the interspecies differences, particularly in terms of metabolism, as illustrated by thalidomide and 13-cis-retinoic acid which are human teratogens although innocuous in murine models [23] , the humanization of this test has been initiated [24, 25] . In these studies, the initial end points were replaced by the analysis of gene expression, representative of one or all of the germ layers. This kind of approach was used recently to validate the embryotoxicity of arsenic(III) and to test a potential antidote [26] .
More focused approaches have been developed in parallel in order to assess the potential neurotoxicity of compounds. Following a two-step differentiation protocol of hESCs into neural progenitors and neuron-like cells, and analysing at each step the expression of selected genes, Stummann et al. [27] have demonstrated that methylmercury, one of the most significant outliers in the initial EST (i.e. this well-known neurotoxicant was predicted to be non-embryotoxic [22] ), interferes mainly with the early stages of neural development. The mechanisms and concentration at which this early developmental toxicity occurs in vitro correlates with the clinical data [27] . These results emphasize the importance of humanization and the inclusion of additional target tissues in order to improve the predictivity of the EST.
Finally, another recent study took advantage of the unique opportunity that hESCs offer to model the embryonic stage to investigate the consequences of maternal smoking during pregnancy [28] . By treating hESCs with nicotine, in a range corresponding to in vivo concentrations, the authors observed deleterious effects on functions that play a crucial role during development, such as cell adhesion, self-renewal and apoptosis [28] .
Differentiation into functional hepatocytes: another classical and essential application for drug discovery
The variety of cellular phenotypes that pluripotent SCs may reach potentially offers pharmacological research access to priority populations, particularly in the field of toxicology.
Numerous cell types derived from pluripotent SCs can find interest here in supplying an 'identity card' of the effects of drug candidates on various tissues of the body. Hepatocytes and cardiomyocytes (Figure 2) are cell types for which there is, until now, no model that collectively satisfies qualitative and quantitative requirements [2,5,6]. Pluripotent SCs are arousing ever-growing attention, as illustrated by the implementation of vast research programmes such as SC4SM (Stem Cells for Safer Medicine) and the European projects Vitrocellomics and Invitroheart, in which academic teams, biotechnological companies and the pharmaceutical industry are working together to investigate the potential of SCs in safety studies.
Hepatocytes have a central role in metabolism that can be explored in vitro. They allow the study of enzymes involved in drug transformation, to identify their metabolites and to anticipate interactions. Any toxicity on these cells must also be detected. The models used at present are primary hepatocytes or immortalized lineages (HepG2 and HepaRG cell lines), which present major limitations in terms of supply and relevance of the metabolic reactions respectively [29] .
Research concerning the differentiation of hESCs into hepatocytes has progressed considerably over the years. It is henceforth possible to obtain hepatocyte-like cells with a yield of 70% in approx. 20 days following threestep approaches, consisting successively in a commitment to definitive endoderm, hepatic induction and a maturation phase [30, 31] . Efficient generation of functional hepatocytelike cells from iPSCs has just been reported [32] . The cells obtained using these protocols display a typical polygonal shape and express many characteristic hepatocyte markers. From a functional point of view, they are able to synthesize and secrete albumin, store glycogen and have transporter activity. Recently, Brolén et al. [33] reported an advanced strategy with a prolonged maturation phase, which enables improvements in many functionalities and the structural organization with hepatocyte-like cells arranged in small islet-like clusters. Hepatocytes express enzymes involved in reactions classically defined as phase I (oxidation of molecules making them more hydrophilic to facilitate their elimination) and phase II (addition of polar groups to increase their solubility). Hepatocyte-like cells obtained following the protocol described by Hay et al. [31] express CYP3A4 [CYP450 (cytochrome P450), family 3, subfamily A, polypeptide 4], a CYP450 isoform responsible for the metabolism of more than 50% of drugs according to phase I reactions. This isoform is functional and reproduces the interaction between midazolam and rifampicin by enzymatic induction. These cells also have a functional CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) which transforms tolbutamide, whereas this drug is not metabolized by the classically used transformed HepG2 cells. Concerning phase II, Soderdahl et al. [34] showed that the profile of subunits which composed the enzyme GST (glutathione transferase) is comparable in hESC-derived and human hepatocytes, whereas GSTA1-1 (GST Alpha 1-1) is underexpressed in HepG2 cells [34] . Moreover, the GST
Figure 2 Pluripotent SCs in predictive toxicology
Human pluripotent SCs and their progeny constitute relevant models to explore various safety issues and could be used to provide an 'identity card' of the effects of drug candidates on diverse tissues of the organism. Taken at the undifferentiated state, they constitute a unique tool to perform developmental toxicology and genotoxicity studies. By differentiation, pluripotent SCs can give rise, theoretically, to all of the different cell types that constitute an organism. Among the more specialized cell types they can model, hepatocytes are of particular interest to the pharmaceutical industry because of their involvement in metabolism. Cardiomyocytes can be used in vitro to detect molecules that induce a delay in ventricular repolarization, in order to prevent the administration of drugs that could lead to ventricular arrhythmia in patients. Pluripotent SC-derived keratinocytes, through their capacity to form a pluristratified epidermis, could also provide models for local tolerance studies (absorption, corrosion, irritation etc.).
is functional and responds to a cocktail of known inducers. That study was performed on cells obtained following less advanced differentiation protocols, and the most recent ones will probably show even more interesting results.
All of these results are extremely encouraging in the attempt to predict hepatotoxicity with greater confidence than with current in vitro and animal models. The use of 3D (three-dimensional) culture as well as co-culture systems, associating, for example, Kupffer and/or endothelial cells with hepatocytes in order to mimic the in vivo hepatic context, are among the strategies now envisaged to reach still more matured cells.
Besides the possibility to give rise to high-fidelity, and thus high-predicitivity, phenotypic models, pluripotent SCs offer the possibility to explore human polymorphisms associated with drug disposition. In a detailed review, Katz et al. [35] described that there would be over 170 gene products, including drug-metabolizing enzymes and transporters, serum-binding proteins and transcription factors, known or expected to have a role in drug disposition, with 16 of them displaying well-established associations between genotype and metabolism [35] . The capacity of hepatocytes derived from genotype-specific iPSCs to reproduce in vivo metabolism diversity is of the greatest interest.
Skin derivatives for large-scale in vitro testing: a challenge for the pharmaceutical, chemical and cosmetic industries
With the progressive implementation of REACH until 2018, which attempts to provide information on the eventual effects of chemicals on human health, and the ban on animal testing for cosmetics already initiated and to be fully effective by 2013, in vitro skin models are stimulating a marked interest not only from the pharmaceutical, but also from the chemical and cosmetics industries (Figure 2) .
The differentiation of hESCs into fairly pure keratinocyte populations has been described recently [36] . An ectodermic commitment can be obtained by growing hESCs for 40 days on a feeder layer in the presence of BMP4 (bone morphogenetic protein 4) and ascorbic acid under conditions adapted from pioneer studies [37] . Keratinocyte-like cells thus display a typical morphology and express characteristic markers, such as keratin 14 and 5 (95% of positive cells), integrin α6 and β4, collagen VII and laminin 5, similar to basal keratinocyte SCs. After 10 days of culture on polycarbonate inserts at the air/liquid interface, these hESCderived keratinocytes demonstrated their functionality by forming a pluristratified epidermis with keratin 14 expression in the basal compartment and keratin 10 in the overlying layers as well as involucrin and filaggrin, late markers of differentiation, in the uppermost layers. The development of a sophisticated pigmented epidermis that is representative of the different phototypes, by co-culture with melanocytes, and the transposition of all of the hESC protocols to iPSCs are examples of the next challenges in this field.
Such pluripotent SC-derived 3D skin models could confer several advantages in terms of quantity, standardization and representativeness of genetic polymorphisms compared with the presently available reconstructed epidermis, obtained with normal human keratinocytes resulting from plastic surgery or neonatal tissues, that are used to predict different drug parameters, such as absorption, sensitization, corrosion, irritation, phototoxicity and genotoxicity, but also inflammation, sun protection and bacterial adhesion as well as cutaneous (de)pigmentation in the case of pigmented epidermis.
Technological challenges for an extended use of pluripotent SCs in drug discovery
The first models derived from pluripotent SCs will be credibly simple, unicellular and first obtained with hESCs before transposition to iPSCs. At the moment, an important challenge consists in making prototype bench assays with the goal to secondarily transpose them to automated, largescale and standardized tests, while taking into account the extremely fast evolution of knowledge in the field of the pluripotent SCs. With an ever increasing number of cell lines, the establishment of standards of characterization becomes essential to allow their comparison and a better understanding of their differences (origin, method of derivation, genetic polymorphism, stability across passages and differentiation potential). Databases, such as the European Human Embryonic Stem Cell Registry (http://www.hescreg.eu/), have been developed to meet such expectations. Concerning culture conditions, the amplification and differentiation protocols must be standardized [38] . This involves trying to avoid co-culture systems, and to work with defined medium and with adapted techniques of dissociation, while not affecting genetic stability [39, 40] . Such developed protocols will have to be easily scalable, with the use of robotic platforms [41, 42] or bioreactors [43] [44] [45] . The differentiation protocols will also have to be optimized to reach a population as pure, homogeneous and mature as possible, with a full characterization of intermediate and terminal populations. It will also be necessary to identify storable progenitors [46] .
Concerning iPSCs, this technology has just started out and requires a number of hurdles to be overcome before its possible industrial use. Therefore intense supplementary work is required to investigate several key parameters, such as the influence of the donor cell type and the reprogramming factors to use as well as a way to introduce them into the cell, with the aim of producing safer approaches inducing minimal genetic alterations [47, 48] . Increasing the reprogramming efficacy [49] and standardizing the different protocols [50] , as well as fully characterizing the reprogrammed cells and their differentiation capacities, are also of major interest.
Once these challenges are met and the added value of these pluripotent SC-derived models has been assessed, a second generation of models will probably arise, combining 3D culture and the associations of several cell types. These approaches should first facilitate access to more advanced stages of maturation, even though it is difficult to imagine that they may ever reach full 'adult' maturation when cultured in vitro. These sophisticated models, intended for a smallscale use, should: (i) allow closer physiological tissular structures to be obtained and, in this way, generate systems with acute predictivity; and (ii) offer the opportunity to explore complex systems such as placental and blood-brain barriers. 
